Miss Oregon an important voice for traumatic brain injury

ali-wWhen I was a freshman in high school, I suffered a traumatic brain injury due to a cheerleading accident.

As someone who had no prior knowledge of brain injuries, it was difficult to understand what I was going through and why I felt so different during my recovery process.

Because of the adversities I overcame as a result of my traumatic brain injury, I wanted to advocate for this serious and often ignored issue.

After meeting with doctors and learning more about traumatic brain injuries, I got involved in volunteering and talking to students about my experiences and recovery process through OHSU’s ThinkFirstOregon program.

Screen Shot 2015-12-16 at 9.40.57 AM

Miss Oregon 2015, volunteering for a Doernbecher Children’s Hospital fundraiser

It was important to me to shed light on an overlooked issue that has not only affected me but so many others.

At the Miss America 2016 competition, I had the opportunity to represent the traumatic brain injury community with a national spotlight.

While at Miss America, I was overwhelmed with the support I received from the TBI community reaching out to me and being thankful for the attention I was able to bring to the issue.

With the constant messages, letters and phone calls from so many who were excited to hear that traumatic brain injuries were finally able to get their due, I realized one voice can really make a difference.

Ali Wallace
Miss Oregon 2015 


Donate to the OHSU Brain Institute
With your support, our scientists can decode the genetic mysteries of neurological disease and create a new standard of care for patients affected by autism, ADHD and other neurodevelopmental disorders.

Learn more at onwardohsu.org/neuro.

Neurology residents teach Milwaukie 5th graders about the brain

Alison Christy, Ittai Bushlin, and Madeline Nguyen at Linwood Elementary in Milwaukie.

Alison Christy, Ittai Bushlin, and Madeline Nguyen in a 5th grade classroom at Linwood Elementary in Milwaukie, OR.

“What have you learned about the brain so far today?”

Hands shot into the air all around the 5th grade classroom at Linwood Elementary.

“I learned that you have to wear a helmet.”

“I knew this already, but that the right side of the brain controls the left side of the body.”

It was an unusual day. As a resident in pediatric neurology, I usually spend my days seeing patients in the hospital or in the clinic, talking about seizures and headaches, medications and MRIs.

That Tuesday, I found myself instead at Linwood Elementary, with neurology resident Madeline Nguyen, M.D.; pediatric neurology resident Ittai Bushlin, M.D., Ph.D.; and Mark Rutledge-Gorman, Ph.D., a researcher who works with the Portland Alcohol Research Center and is active in outreach to local schools.

We were having a blast.

“What kinds of things can a baby do?”

“Eat!” “Cry!” “Sleep!”

“Right, a baby’s brain only has to do a few things. But it’s learning and growing all the time. What can you do? What can your brain do?”

“Learn!” “Play sports!” “Read and write!”

“What about your teacher? What does her brain have to do?”

“She has to teach us!” “She has to make us stop talking!” “She has responsibilities!”

A few weeks before that day, Madeline, Ittai and I met with Mark to plan our time with the kids. Mark has been teaching kids about science, the brain, and the dangers of addiction for fifteen years. He has Powerpoint slides and a big plastic bin with modeling clay, brain coloring pages (for making brain hats) and other activities.

The aim, he said, was to teach them that their brains are still developing, and that they can influence how it develops. There are other aims too, like learning decision-making, or developing empathy.

If your little sister is annoying, maybe that’s just because her brain is less developed than yours. If your teacher is telling you to sit in your seat, maybe that’s because her brain is more developed than yours, and because she is responsible for your safety and your education.

While Ittai squished and rolled clay brains with half the class, I gathered the other half around a blue bucket.

"Have you ever touched a brain?"

“Have you ever touched a brain?”

“What will happen if you drop this egg into the bucket?”

“I know! I know! It will break.”

“Is that our hypothesis? What’s a hypothesis?”

“It’s a test!” “No, it’s a question!”

A brown-haired girl dropped the egg. It cracked, but didn’t break. Hypothesis tested.

“Let’s come up with another hypothesis. What will happen if I wrap this egg in newspaper and bubble wrap and put it in this box, then drop it into the bucket?”

The same girl dropped the wrapped egg. No cracks!

“Now let’s talk about helmets. How does a helmet protect your brain?”

Why did we all choose to spend that rainy Tuesday afternoon at Linwood Elementary?

First of all, we were there to help the kids learn about ways to protect their brains, by wearing helmets and avoiding alcohol and drugs.

There isn’t always enough time in a doctor’s appointment to explain not only what a child should do to be healthy, but why it’s necessary.

Hopefully, some of those children will think twice before getting on a bicycle without a helmet, or taking a first sip of alcohol.

Mark, Madeline, Ittai and I are also people who love science and the incredible things the brain can do, and we hope that our love might be infectious.

It never occurred to me that I could get a Ph.D. until I met professors when I was in high school. I didn’t think about getting a medical degree until I met doctors who did science and realized that those things could work together.

Maybe some of the kids in this class will see these doctors and scientists who are clearly very excited about brains, and start thinking that they, too, could study medicine or science.

And there’s another ulterior motive.

“Does anyone have any last questions?”

A boy stood up, his hand raised high.

“Have you ever touched a brain?”

I have. It was pretty cool. Sometimes I forget that what I get to do, every day, is amazing. There is nothing like the enthusiasm of a 5th grader to remind me that I am so lucky to have this awesome job.

I hope he gets to touch a brain someday.


Alison Christy, M.D., Ph.D.
Pediatric neurology resident
Oregon Health & Science University


Donate to the OHSU Brain Institute
With your support, our scientists can decode the genetic mysteries of neurological disease and create a new standard of care for patients affected by autism, ADHD and other neurodevelopmental disorders.

Learn more at onwardohsu.org/neuro.


Valerie Palmer recognized for innovative social-impact contributions

Valerie Palmer, faculty instructor at OHSU, was recently selected by Encore.org as one of 41 Purpose Prize Fellows for her work creating an education exchange, bringing services to immigrant refugees and raising health-care professionals’ cultural awareness and cooperation.

Encore.org is a national nonprofit that is building a movement to tap the experience of people in midlife and beyond who are using their encore years – the time of traditional retirement – to undertake powerful social-impact projects.

Valerie S. Palmer

Faculty Instructor, Oregon Health & Science University (OHSU) and Board President, Immigrant Refugee and Community Organization, Oregon Health & Science University, Global Health Center
Purpose Prize Fellow 2015

Struggle to understand and prevent brain diseases in children;  a global problem

The struggle to understand and prevent brain diseases in children; a global problem

I was born in South Africa under apartheid. As a person of mixed race, my skin color led to discrimination, in society and within my family. As the oldest girl, I looked after my siblings, cleaned house, prepared meals, cared for farm animals and walked miles to school each day. And when I was sick, I had compassionate medical care from a beloved local physician, whose respect for life stood in sharp contrast to the apartheid regime.

At 17, I left South Africa, eventually finding sanctuary in the United States, where I acquired freedom, education and full enfranchisement previously denied.

My early research stimulated me to create a nonprofit focused on health disorders in low-income countries. Later, in the field and laboratory, I explored neurological disorders across the world. In 2007, when the OHSU Global Health Center opened, I began to share my knowledge with students entering the health professions….

Continue reading Valerie’s story at Encore.org

Learn more:
Conference paper on research conducted in Gulu, Uganda
Inter-professional Community Health & Education Exchange (iCHEE)
The Oregonian: “OHSU program gives immigrants, the unemployed and underemployed a way to get health checkups”


Donate to the OHSU Brain Institute
With your support, our scientists can decode the genetic mysteries of neurological disease and create a new standard of care for patients affected by autism, ADHD and other neurodevelopmental disorders.

Learn more at onwardohsu.org/neuro.


Give Time: 3 ways to increase face-to-face contact with loved ones

With Thanksgiving just behind us and the end-of-the-year holiday seasons fast upon us, our minds often turn to our loved ones.

In my family, we have made a conscious effort (and yes, with airfares these days, not a cheap one either!) to gather with an assortment of family members around Thanksgiving and Christmas.

Though it can be an effort to meet up with family and friends, recent research brings home the point that this extgive-time-neuroFBra effort likely translates into significant benefits for our mental well-being.

In a study I led examining data from over 11,000 adults over age 50, we found that those regularly spending face-to-face time with friends and family had significantly reduced risk of developing clinically significant symptoms of depression years later.

Other modes of having social contact—calls on smart phones, emails and letters—were not robustly associated with depression.

Here I offer a few practical tips to keep in mind as you prepare for the holidays.

Schedule face-to-face visits with friends and family into your monthly calendar.

The more often you spend time face-to-face the better, but our data showed that even those who got together once or twice a month had significantly lower rates of depressive symptoms. Just like other important activities in your life, make sure you schedule it in!

Don’t get together if it’s going to stress you out.

Social relationships contribute to our happiness and healthiness, but they actually do more damage if the relationship is toxic. Face time should be fun time, not argument time.

For those with loved ones far away, try to develop local support networks for them.

Let’s face it: if your parents live 3,000 miles away, it is not realistic to get together every week with them. However, if you can see to it that they join a club or social group (pick one based on their hobbies or interests), they can get together weekly and offer similar mental health benefits.

Detailed results from our study are published in the Journal of the American Geriatrics Society.




Alan R. Teo, M.D., M.S, Assistant Professor of Psychiatry at OHSU and Core Investigator, VA Portland Health Care System.





Donate to the OHSU Brain Institute
With your support, our scientists can decode the genetic mysteries of neurological disease and create a new standard of care for patients affected by autism, ADHD and other neurodevelopmental disorders.

Learn more at onwardohsu.org/neuro.

Cleaning while we sleep: A novel approach in Alzheimer’s research

ThinkstockPhotos-490755478Every 67 seconds, an American develops Alzheimer’s disease. It affects 5.3 million people in the US and if no medical breakthroughs to prevent or cure the disease are found, this number will triple by 2050.

In 2013, Jeffrey Iliff helped discover how our brains flush out toxic waste as we sleep. This is waste that builds up in our brains during the day – including the Alzheimer’s-linked protein, amyloid beta.

His findings, which he’s advancing by the day, could potentially lead to the treatment, and maybe even prevention, of Alzheimer’s. We catch up with him to find out about how his work has developed over the past few years, the unforeseen twists and turns that led him down this important avenue, and what he looks for in the next generation of Alzheimer’s researchers.

Why are our sleeping brains pertinent to our brain cleansing system?

It seems that sleep has evolved to maximize a bunch of maintenance-type functions in our brain, and this cleaning process one is just one of them. It’s arguably not even the most important one. But for whatever reason, our brain function is optimized when these housekeeping functions happen during sleep, allowing us to maximize our performance while we’re awake.

But why that is we don’t really know yet.

You helped discover an important potential link between sleep and the development of Alzheimer’s disease. What were your key findings?

There are two main findings in our research that everything else rests on. The first is in a paper we published in 2012 about cerebrospinal fluid circulation. This is the fluid that surrounds the brain. We were able to show that a substantial portion of it is actually recirculating back into and through the brain.

It does this by essentially using the blood vessels as a scaffold to provide access to the entire brain tissue. The movement of this fluid along vessels and through the spaces between the brain’s cells appears to be involved in the clearance of amyloid beta out of the brain interstitial fluid.

The second main finding relates to a paper we published in 2013. Here, we showed that this cleaning process is primarily a feature of the sleeping brain. Both the movement of cerebrospinal fluid along the outside of blood vessels and back through the brain, and the clearance of amyloid beta, occur much more rapidly in a naturally sleeping and anesthetized brain, compared to the waking brain.

How has your research developed since this finding? What new information have you brought to light?

To boil it down, our current research focus is essentially to analyze what’s going wrong within this cleaning system at a molecular level, and then to translate that into human subjects.

Firstly, our last few papers have shown that in both the aging and injured mouse brain, this cleaning of the brain slows down. We want to define on a molecular and cellular level what’s going wrong in the aging and injured brain that’s slowing down this process, and whether that makes it vulnerable to amyloid beta deposition or tau aggregation.

But at this point, none of this work has been validated in humans – we don’t really know if this cleaning process happens in the human brain during sleep, much less whether this process contributes to the development of Alzheimer’s in people.

So I’m excited that we’ve received funding from the Paul G. Allen Family Foundation to look into this. They are funding our group to extend our work on sleep and the aging brain – essentially from mouse models into humans.

The first step in that process is to develop clinical imaging approaches to measure the system’s activity in the sleeping and waking human brain. The study will then move on to analyze that process in the aged human brain, and in the brains of people who appear to have the beginnings of Alzheimer’s disease.iliff-ted

How might your research and recent developments help prevent Alzheimer’s disease?

The encouraging thing is that there’s an increasing push on the therapeutics’ side to identify people who don’t have Alzheimer’s disease yet, but are expected to at some point in the future. That’s one of the motivations behind the development of amyloid PET imaging and cerebrospinal fluid biomarkers, for example.

A study that just came out of Washington University in St. Louis reported that CSF biomarkers consistent with Alzheimer’s disease could be detected as early as 45 to 55 years of age. If amyloid deposition begins that early, then it’s possible the failure of this clearance system is happening even earlier.

So, if we can develop imaging approaches that aren’t prohibitively invasive, then it may be possible to identify people who may be susceptible to amyloid beta deposition in the decades to come. That would offer a very wide window for lifestyle interventions, or drug therapies if effective drugs can be developed.

That’s the really exciting and promising thing for the future: First, this cleaning system may be a new therapeutic target, and imaging it may allow us to develop a new biomarker that identifies vulnerability at an earlier stage in the disease process than our current biomarkers can.

How long do you think it will take to reach this point?

A number of important things still need to be done. I think we’ll know whether these ideas have legs and traction in the next three to five years. If the function of this system can be validated in human subjects, and if its impairment can be causally linked to amyloid beta deposition, then things move on to identifying drugs that might modulate this pathway. That can go quickly or slowly depending on what the data looks like.

Has your research taken any unexpected turns?

The magnitude of the sleep-wake effect was very surprising. But admittedly, all of this research has been one big, unexpected turn that we’ve been trying to chase and learn from along the way.

My background isn’t in Alzheimer’s disease or sleep at all – it’s in vascular physiology. I started my postdoc in a glial cell biology lab and thought I’d be a basic science researcher for the duration of my career. The shift to clinical subjects and clinical samples wasn’t something I anticipated, but it’s probably been the most exciting thing that’s happened in my career.

What event sparked the change in your career?

Jeffrey Iliff, Ph.D.

Jeffrey Iliff, Ph.D.

For my PhD, I studied the regulation of brain blood vessels, which is really a largely vascular subject. At the beginning of my post doc I went to talk to my supervisor, Maiken Nedergaard, and she showed me a paper written in 1984. It was by the American neuroscientist Patricia Grady about the movement of cerebrospinal fluid tracers into the brain along blood vessels, and was a somewhat controversial paper at the time.

I was only five years old when the study came out, so when Maiken said, “I want you to redefine water movement in the brain,” I had almost no idea what that meant at all! It was a whole field that at the time I knew nothing about, and she knew very little about.

So, almost from day one it was like we were wandering out into the middle of nowhere, and then we happened to hit this major road – a road that has been very, very interesting. And we’ve been working on it together, and then separately in our own labs, ever since.

What was your greatest ‘eureka’ moment in the lab?

The biggest eureka moment for me was when I was doing the dynamic imaging of the vasculature in the brain. I now use these videos in every talk that I give because they are so evocative. It’s like this: the blood vessels are always red and the tracer we inject into the cerebrospinal fluid circulation is always green.

You see the red blood vessels there, and then the green tracer runs into the screen along the outsides of the vessels – it forms a halo around the blood vessel as it moves through the perivascular space.

The first time I saw that it really struck me because I was expecting something very, very different. I thought the green cerebrospinal fluid would flood over the screen, for example. But instead, it was restricted to this very narrow, anatomical pathway; it was so specific in where and how it moved.

The fact I could see it happening in front of my eyes in real-time, and follow and chase it around, made it very real for me. And then the videos that come from this imaging are extremely believable and compelling for other people, too – in a way that an image of fixed tissue in a paper isn’t. So that was a big moment – one that drove me forward in my research.

You have a postdoctoral position open in your lab. Do you have any advice or tips for people thinking of applying, or for those entering your area of research?

When I’m looking for a post doc I’m not looking for a technician. I can get hands – that’s not a problem. What I want is people who have better ideas than I do; I want people in my lab who are more creative than I am, and that can bring something new that’s going to change my science.

Having a different background is extremely valuable because you can offer a new take on the science that we’ve been looking at the same way for the last 5 years.

I’m also looking for someone who has a defined idea of what they want to do when this post doc is over. Many applicants don’t have a clear vision of how they’re going to become an independent researcher – which is an end goal I hear a lot.

My goal is to help them get there, I’d love to do that. But if they haven’t thought of how their science and my science can interact in a way to get them there, then they’re missing a critical step.

In the interview I want to see this drive, energy, creativity, and familiarity with our work. And that’s because when I hire for these post doc positions, I’m looking for a potential partner.

This story was originally published on ResearchGate News to highlight the work of neuroscientist Jeffrey Iliff (Oregon Health & Science University) for this year’s World Alzheimer’s Day on September 21, 2015.

OBI’s Bobby Heagerty featured at national meeting

The Society for Neuroscience (SfN) held its 45th annual meeting in Chicago recently, attracting 30,000 neuroscientists from around the world to the windy city.

Photo credit: Bill Griesar, NW Noggin

Photo credit: Bill Griesar, NW Noggin

Bobby Heagerty, director of community education and outreach for the OHSU Brain Institute (OBI), was asked to participate as a keynote speaker for the workshop on Brain Awareness.

Introduced by Steve Hyman, president of SfN, and attended by several hundred participants, Bobby’s presentation made five key points to how to create a successful public engagement campaign: organization, promotion, constituency data, leverage and connections.

In her typically enthusiastic manner, Bobby joked that being organized and a promoter can also be equated to being a border collie and cheerleader. To get the group through the gate requires resourcefulness and attention; and standing up to brag about the latest in neuroscience can only lead to more connections.

Keeping the public engaged and informed about this latest neuroscience is vital, and every event should include a way to collect contact information for interested constituencies – clip boards are key!  A strong support group standing behind your platform provides leverage to run with ideas.

And finally, in her own words, “All of these individuals, programs, initiatives, events and mechanisms should be seen as part of weaving a gorgeous tapestry.”

Photo credit: Bill Griesar, NW Noggin

Photo credit: Bill Griesar, NW Noggin

Bobby is the 2013 winner of SfN’s Educator of the Year Award, and started the Brain Awareness Season in Portland in 2000.

Over the years, she has grown the program from a small lecture at a local church, to a five-part series at the Newmark Theater featuring national speakers, a brain fair at OMSI, a SfN Oregon Chapter meeting, and a Teacher Workshop.

It’s no wonder she was asked to pass along her keys to success to this international crowd!

The Society for Neuroscience is a non-profit organization with nearly 40,000 members around the world, the largest group of scientists and physicians working to learn more about the brain and nervous system.

The Oregon Chapter, one of 130 chapters worldwide, is led by Dr. Larry Sherman, senior scientist in the Division of Neuroscience at the Oregon National Primate Center. The Chapter’s annual meeting will take place in May 2016.




Kate Stout is the Program Coordinator, Community Education and Outreach for the OHSU Brain Institute.



Five things you should know when caring for a loved one with dementia

Caregiving for a loved one with dementia can be challenging to your family dynamics, your finances, and more. But did you know, it can also be hard on your emotional and physical health?

Research shows that caregivers for persons with dementia are more vulnerable to health problems such as hypertension, diabetes, depression, anxiety and insomnia.

It is important that caregivers take care of themselves as well as their care-recipients.

1. Find, and attend, a support group.

It takes effort to find, and actually attend, a support group, but the effort is worth it. Support groups offer information, guidance, and well, support. It is important to be around others who understand what you are going through.

The Alzheimer’s Association has a variety of support groups across Oregon that serves caregivers and their care-recipients.

Know that the Alzheimer’s Association serves everyone with memory loss, not just Alzheimer’s.

2. Call your county’s Family Caregiver Support program.

The Multnomah County program provides a wealth of information and can connect you to a variety of helpful services. They may even be able to pay for assistance for you- such as a massage, a care provider to give you a break, a gym pass, etc.

This program is free to all and helps people from all walks of life.

3. Find activities outside the home for your family member with dementia.

This will give your family member a chance to get out of the house and give both of you a break. Both the Family Support Program and the Alzheimer’s Association can help you find classes or adult day programs for persons with dementia.

4. Exercise!

Exercise will help your mood and stress levels and protect your body over the years. A good exercise program will also help you sleep better at night.   Find an activity that you enjoy and make sure it gets your heart rate up. A good starting point is to walk with hand weights. Even better–attend an exercise class at a local community center.

5. Ask for help.

What if you can’t do any of the above? Some caregivers are so busy they have little time for self-care.

I recommend picking up the phone and calling either the Family Caregiver Support Program at 503-988-3646 or the Alzheimer’s Association at 1-800-272-3900.

Tell them, “I am a caregiver, I need support, but I don’t know how to do this.”

They will take it from there—and you’ll be glad you called.

The main message I want to convey is to reach out to others for support—even if you think you don’t need it.

You don’t have to walk this road alone—there are people standing by who can, and want, to help!




Allison Lindauer, N.P., Ph.D. is an Assistant Professor at The Layton Aging and Alzheimer’s Disease Center.

Early diagnosis of Alzheimer’s disease is key goal for OHSU researchers

Alzheimer’s disease is the most common form of dementia and is the sixth leading cause of death in the United States.

Symptoms include memory loss, personality changes and trouble thinking, and the disease typically worsens over time.

Julie Saugstad, Ph.D. and Joseph Quinn, M.D.

Julie Saugstad, Ph.D. and Joseph Quinn, M.D.

Current treatments cannot stop the disease from progressing, but they can slow the development of symptoms temporarily.

Clinical diagnosis is determined by noting the degree of a patient’s mental decline, which is not obvious until there is severe and permanent brain damage.

There are no biomarkers that can be used to predict the onset or distinguish early Alzheimer’s from age-related memory loss.

Extracellular RNA (exRNA) communication is a recently discovered cell-to-cell signaling process that holds enormous promise for improving our understanding of a wide variety of diseases.

In 2013, the NIH Common Fund provided support for 30 research projects designed to explore and enhance scientists’ understanding of exRNA communication in normal and disease states.

18 of these grants were administered by the NCATS including our UH2/UH3 grant to study the clinical utility of microRNAs (small RNAs that do not code for protein) in cerebrospinal fluid as biomarkers of Alzheimer’s.

The Oregon Alzheimer’s Disease Center (OADC), the core program of the OHSU Layton Aging & Alzheimer’s Disease Center, holds CSF samples donated from AD patients and control subjects.

In the UH2 discovery phase, our studies using samples from the OADC revealed approximately 30 microRNAs that are different between Alzheimer’s disease and control cerebrospinal fluid.

In the newly funded UH3 phase, we will validate expression of these microRNAs in a new and larger set of cerebrospinal fluid samples.

Our long-term goals are to detect changes in microRNAs earlier in the disease process, which would allow patients to start treatments sooner and possibly slow or prevent brain function decline and damage, and to potentially gain new information regarding the underlying cause of Alzheimer’s disease.

UH2/UH3 Team:
Julie Saugstad, Ph.D. – Anesthesiology & Perioperative Medicine
Joseph Quinn, M.D. – Neurology
Theresa Lusardi, Ph.D. – Legacy Research Institute
Jodi Lapidus, Ph.D. – Biostatistics
Christina Harrington, Ph.D. – Integrated Genomics Laboratory

Acupuncture and diet changes to treat neuropathic pain

Peripheral Neuropathy is a common neurologic condition, which affects the peripheral nerves. The most common symptoms associated with peripheral neuropathy are burning, tingling pain, which often feels like sharp electric sensation.

Walking, especially on hard or cold surfaces can be very painful, often described as walking on ground glass or stepping on pebbles. When large nerve fibers are involved, patients are more likely to experience sensory loss and weakness in the feet and sometimes hands.painful_feet_L-286x300

Small (microscopic) fiber involvement is typically limited to painful sensory symptoms. Often there are changes in the skin such as thinning and body hair loss, as well as muscle wasting in the feet and hands.

There are many common causes of peripheral neuropathy in the US. This includes diabetes, thyroid disorders, certain auto-immune conditions, vitamin B12 deficiency, alcohol abuse and exposure to toxins such as heavy metals or chemotherapy drugs. HIV, other infections and certain types of cancer can also cause this type of pain.

Clinicians and patients alike are well aware of how difficult it is to treat peripheral neuropathy.

In 2011 the American Academy of Neurology issued the latest guidelines for treatment of neuropathic pain and recommended that 4 therapeutic agents are probably effective for the treatment of neuropathic pain – pregabalin (Lyrica), gabapentin (Neurontin), duloxetine (Cymbalta) and amitriptyline (Elavil).

Unfortunately, these medications are for symptomatic management only and do not affect the disease course and they have various side effects including sedation, leg swelling, paradoxical agitation and weight gain.

It may be worth trying certain dietary changes, aimed to reduce systemic inflammation.

Diet modifications

Gluten intolerance has been reported in as high as 34% of patients with unexplained peripheral neuropathy. While positive blood tests for Celiac Disease are diagnostic, it may be worth trying a 4-6 week trial of strict gluten-free diet, regardless of test results as certain patients may have gluten intolerance and test negative for celiac disease.

Other dietary changes include a trial of lactose-free diet or refined carbohydrate-free diet, as both are known to be pro-inflammatory and may increase pain sensation. These dietary trials should be performed sequentially and for 4-6 weeks at a time.



Recently we examined the evidence for acupuncture in the treatment of peripheral neuropathy. We systematically reviewed 46 clinical trials and included 13 qualifying randomized controlled trials of acupuncture against sham acupuncture or standard medical therapy and concluded that acupuncture is effective in the treatment of diabetic neuropathy, Bell’s palsy, Carpal Tunnel Syndrome and it is most likely effective for the treatment of HIV-related neuropathy.

In the Neurology Wellness Clinic at OHSU we routinely treat patients with peripheral neuropathy and some of our best results are with idiopathic neuropathy (meaning of unknown cause). A typical treatment course consists of weekly sessions with electroacupuncture for 6-8, sometimes 10 weeks, followed by gradual spacing out to every other week, every third week, once a month and eventually maintenance treatment once every 2-3 months.



Alexandra Dimitrova, MD is an Assistant Professor in Neurology at OHSU, who sees patients with headache and pain in the
Neurology Wellness Clinic. In her practice she integrates traditional neurologic treatments with acupuncture, dietary and lifestyle changes and other complementary and integrative treatments.

A look back at a neuroscience meeting of the minds in the Pacific Northwest

Earl Blumenauer

Congressman Earl Blumenauer (D-OR)

A Congressman, a National Institutes of Health (NIH) director, a leader of a national advocacy group, and a scientist-turned-advocate shared a stage last month in Portland, OR, to talk about the importance and impact of neuroscience research nationwide.

This Neuroscience Town Hall was the final event of the NeuroFutures conference, organized and sponsored by the OHSU Brain Institute, the University of Washington, and the Allen Institute for Brain Science, which brought together scientists and clinicians in the Pacific Northwest to share recent discoveries in basic and translational neuroscience research.

Prior to the town hall, attendees browsed the gallery of 11 patient advocacy groups during the cocktail hour, including the Oregon chapters of the Alzheimer’s Association and NAMI, and the Parkinson’s Resources of Oregon, just to name a few.

Indeed, advocacy was the central topic for all of the speakers of the town hall.

Congressman Earl Blumenauer (D-OR) opened the discussion with praise for the “ecosystem for innovation in research” that exists in the Pacific Northwest, citing a history of positive collaborations between advocates, scientists, physicians, and the public. This collaborative environment is essential for “focusing on the overall arena of neuroscience,” which is the goal of the Congressional Neuroscience Caucus that he founded in 2010.

Caucus events are standing room only, which he attributes to the nature of the topic: “Neuroscience is one of the few areas that actually brings people together… intrigues instead of divides.”

Walter Koroshetz

Dr. Walter Koroshetz, director of the National Institute of Neurological Disorders and Stroke (NINDS)

In a light-hearted turn in the conversation, Congressman Blumenauer jokingly suggested that perhaps neuroscience can help us answer the question of “why well-educated Republicans are more skeptical of the science than well-educated Democrats,” especially with respect to climate change.

But all jokes aside, the Congressman emphasized that we do need “objective, analytical ways to get these points across… for the betterment of society,” and neuroscience could be the catalyst for reaching across the aisle.

Next to speak was Dr. Walter Koroshetz, director of the National Institute of Neurological Disorders and Stroke (NINDS), who started his segment with “What he said, that’s what I think too,” prompting laughter from the crowd.

Dr. Koroshetz emphasized that the NIH is able to fund over $31 billion in research grants, because of the generosity of tax payers. In fact, the NIH is a great analogy to the electoral system, since the NIH structure is very democratic: “anyone can submit a grant, and grants are reviewed by peers.”

Mark Rasenick

Dr. Mark Rasenick, Professor at the University of Illinois, Chicago, and chair of the Advocacy Committee for the American Brain Coalition

From an NIH funding perspective, Dr. Koroshetz told the audience “Current public health issues are heavily weighted towards neurological issues.”

He echoed the Congressman’s sentiment that we need a unified neuroscience effort, and that The White House BRAIN Initiative “floats all boats,” instead of focusing on certain diseases.

Support for basic research is imperative: “A recent major advancement in neuroscience comes from organisms that are more basic than bacteria”, speaking about optogentics, with allows us to turn individual nerve cells in the living brain on and off with light.

In order to “reduce the burden of mental health disorders in this country,” Dr. Koroshetz concluded with the need to bring together basic research, disease research, and patient support.

Dr. Mark Rasenick, Professor at the University of Illinois, Chicago, and chair of the Advocacy Committee for the American Brain Coalition, started his remarks by asking the crowd how many of us have participated in advocacy events. Only a handful of attendees raised their hands. Dr. Rasenick advised the audience: “To increase the enterprise of neuroscience, all of us need to be engaged… in activities on the Hill.”

As a scientist and advocate, the question turns to what to lobby for, since there is not enough money to go around.

Katie Sale

Katie Sale, Executive Director of the American Brain Coalition

From this perspective, lobbying for neuroscience research in general, in addition to specific diseases, will bring support for the field as a whole.

Dr. Rasenick concluded with a fantastic analogy for engagement across sectors: “Neuroscience is a big tent, and we all need to live in that tent, and tighten the wires to make that tent supportive.”

Katie Sale, Executive Director of the American Brain Coalition (ABC), piggy-backed on this analogy and the theme of the night: “We need to speak with one voice, and bring everyone together.”

As the nation’s largest organization of neuroscience-focused patient advocacy groups, the ABC is doing exactly that. Working through the Congressional Neuroscience Caucus, the ABC pulls together a clinician, a scientist, and a patient advocate for briefings on a wide range of topics – from mental illness and neurodegenerative diseases, to the effects of physical activity and music on the brain.

Summing up the collaborative spirit echoed by all the speakers, Ms. Sale concluded the night with a positive sentiment: “Step by step, we can all make a difference.”




Kateri Spinelli, Ph.D. is a post doctoral fellow in the Department of Neurology.


Participation Guidelines

Remember: information you share here is public; it isn't medical advice. Need advice or treatment? Contact your healthcare provider directly. Read our Terms of Use and this disclaimer for details.